Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 11/20 | 0.61 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.36 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.36 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3586535 | 0.89 | PNMT (0.49) | PNMTPARP1KCNH2PARP2ASIC3 | |
| SCHEMBL3004190 | 0.86 | PNMT (0.44) | PNMT | |
| SCHEMBL29356870 | 0.84 | PNMT (0.47) | PNMTPARP1KCNH2PARP2ASIC3 | |
| SCHEMBL5557141 | 0.82 | PNMT (0.42) | PNMT | |
| SCHEMBL21236155 | 0.78 | PNMT (0.63) | PNMTPARP1PARP2ASIC3CD44 | |
| SCHEMBL23142158 | 0.77 | PNMT (0.42) | PNMTPARP1KCNH2PARP2ASIC3 | |
| SCHEMBL17613134 | 0.76 | PNMT (0.61) | PNMTPARP1PARP2ASIC3CD44 | |
| SCHEMBL6424327 | 0.76 | PNMT (1.00) | PNMTASIC3CD44MAOBTPSAB1 | |
| SCHEMBL12126395 | 0.76 | PNMT (0.61) | PNMTPARP1KCNH2PARP2CD44 | |
| SCHEMBL1427612 | 0.76 | PNMT (0.61) | PNMTPARP1PARP2ASIC3CD44 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311853-B | Triazole derivatives and their use in agriculture | 东莞市东阳光农药研发有限公司 | 2020-02-11 | — | — | CN | disclosed |
| CN-1993324-B | 3-(((4-phenyl)-piperazin-1-yl)-alkyl)-3-alkyl-1,3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders | EGYT GYOGYSZERVEGYESZETI GYAR | 2010-12-15 | — | — | CN | disclosed |
| US-7786129-B2 | Piperazine derivatives of dialkyl oxindoles | EGIS GYOGYSZERGYAR NYRT (HU) | 2010-08-31 | — | — | US | disclosed |
| CN-100572377-C | The indol-2-one derivates of treatment nervus centralis obstacle, gastrointestinal disorders and cardiovascular disorder | EGIS PHARMACEUTICAL WORKS (HU) | 2009-12-23 | — | — | CN | disclosed |
| US-20090306144-A1 | PYRIDINE DERIVATIVES OF ALKYL OXINDOLES AS 5-HT7 RECEPTOR ACTIVE AGENTS | VOLK BALAZS | 2009-12-10 | — | — | US | disclosed |
| US-20090281137-A1 | INDOL-2-ONE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS, GASTROINTESTINAL DISORDERS AND CARDIOVASCULAR DISORDERS | VOLK BALAZS | 2009-11-12 | — | — | US | disclosed |
| EP-1751138-B9 | INDOL-2-ONE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS, GASTROINTESTINAL DISORDERS AND CARDIOVASCULAR DISORDERS | EGIS GYOGYSZERGYAR NYRT (HU) | 2008-11-12 | — | — | EP | disclosed |
| EP-1751138-B1 | INDOL-2-ONE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS, GASTROINTESTINAL DISORDERS AND CARDIOVASCULAR DISORDERS | EGIS GYOGYSZERGYAR NYRT (HU) | 2007-12-26 | — | — | EP | disclosed |
| US-20070265300-A1 | Pyridine Derivatives of Alkyl Oxindoles as 5-Ht7 Receptor Active Agents | EGIS GYOGYSZERGYAR RT. (HU) | 2007-11-15 | — | — | US | disclosed |
| US-20070232619-A1 | Piperazine Derivatives of Dialkyl Oxindoles | EGIS GYOGYSZERGYAR RT. (HU) | 2007-10-04 | — | — | US | disclosed |
| CN-101010313-A | Indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders | EGIS PHARMACEUTICAL WORKS (HU) | 2007-08-01 | — | — | CN | disclosed |
| CN-1993324-A | 3-(((4-phenyl)-piperazin-1-yl)-alkyl)-3-alkyl-1,3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders | EGIS GYOGYSZERGYAR NYRT (HU) | 2007-07-04 | — | — | CN | disclosed |
| CN-1976917-A | Pyridine derivatives of alkyl oxindoles as 5-HT 7 receptor active agents | EGIS GYOGYSZERGYAR NYRT (HU) | 2007-06-06 | — | — | CN | disclosed |
| EP-1776339-A2 | 3-(((4-PHENYL)-PIPERAZIN-1-YL)-ALKYL)-3-ALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | EGIS Gyógyszergyár Nyrt (HU) | 2007-04-25 | — | — | EP | disclosed |
| WO-2005109987-A9 | 3-(((4-PHENYL)-PIPERAZINE-1-YL)-ALKYL)-3-ALKYL-1, 3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | EGIS GYOGYSZERGYAR NYRT (HU) | 2007-03-29 | — | — | WO | disclosed |
| EP-1751138-A1 | INDOL-2-ONE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS, GASTROINTESTINAL DISORDERS AND CARDIOVASCULAR DISORDERS | EGIS Gyógyszergyár Nyrt (HU) | 2007-02-14 | — | — | EP | disclosed |
| EP-1751134-A1 | PYRIDINE DERIVATIVES OF ALKYL OXINDOLES AS 5-HT7 RECEPTOR ACTIVE AGENTS | EGIS Gyógyszergyár Nyrt (HU) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005109987-A2 | 3-(((4-PHENYL)-PIPERAZINE-1-YL)-ALKYL)-3-ALKYL-1, 3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | EGIS GYÓGYSZERGYÁR NYRT. (HU) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005108388-A1 | PYRIDINE DERIVATIVES OF ALKYL OXINDOLES AS 5-HT7 RECEPTOR ACTIVE AGENTS | EGIS GYÓGYSZERGYÁR NYRT. (HU) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005108390-A1 | INDOL-2-ONE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS, GASTROINTESTINAL DISORDERS AND CARDIOVASCULAR DISORDERS | EGIS GYÓGYSZERGYÁR NYRT. (HU) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232619-A1 | Piperazine Derivatives of Dialkyl Oxindoles | TPH2, DRD3, CNR2 | PNMT 755/4885PARP1 3285/4885KCNH2 288/4885 |
| US-20090306144-A1 | PYRIDINE DERIVATIVES OF ALKYL OXINDOLES AS 5-HT7 RECEPTOR ACTIVE AGENTS | HTR7, HTR2C, HTR1A | PNMT 66/4885PARP1 2782/4885KCNH2 1575/4885 |
| US-20070265300-A1 | Pyridine Derivatives of Alkyl Oxindoles as 5-Ht7 Receptor Active Agents | HTR7, HTR2C, HTR1A | PNMT 64/4885PARP1 2814/4885KCNH2 1219/4885 |
| US-20090281137-A1 | INDOL-2-ONE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS, GASTROINTESTINAL DISORDERS AND CARDIOVASCULAR DISORDERS | TPH2, TPH1, IDO1 | PNMT 44/4885PARP1 3595/4885KCNH2 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.